The first fund-of-funds introduced by the UK Department for Business, Innovation and Skills was the Enterprise Capital Fund (ECF) programme in 2006. Managed by private fund managers, ECFs focus on early-stage and growth-stage SMEs in sectors like technology, life sciences, and clean energy. Fund managers are required to raise at least one-third of their total capital from private investors (Ipsos Mori; George Barret, 2021[25]). The scheme features an asymmetric returns structure, favoring private investors with higher profit shares while granting the BBB a 3% prioritized return after capital repayment. This structure has been well-received by fund managers and has resulted in higher returns for private investors compared to the broader UK VC market.
Since its inception, the program has supported 39 private funds and 705 portfolio companies, with the BBB committing GBP 1.85 billion as of April 2023, including GBP 208 million in the 2021/2022 fiscal year (British Business Bank, 2021[26]). The average size of ECF-supported funds is GBP 47 million. By 2019, the programme had significantly increased the supply of VC for early-stage companies by enabling faster deal closures, larger fund sizes, and helping fund managers raise successor funds. Private investors contributed 45% of the total funding across the 14 ECFs evaluated. The impact of the programme on the companies funded by funds participating in the ECF has been notable. Between 2011 and 2019, the 388 firms funded by ECFs created nearly 8,000 jobs and generated GBP 2.2 billion in additional sales. These companies experienced remarkable growth, with annual turnover increasing by 76% and employment by 48% (Ipsos Mori; George Barret, 2021[25]).
In 2017, the UK Government published the Patient Capital Review, which identified a financing gap in the scale-up phase corresponding to investment tickets of GBP 5 million and above. This prompted the creation of the Managed Funds Programme (2017) and the British Patient Capital Programme (2018) to foster long-term and large investment tickets into growth-stage companies.
The Managed Funds Programme (MFP) aims to attract institutional investors and is administered by British Business Investments (BBI), a subsidiary of the BBB (British Business Bank, 2022[27]). The programme invests in large-scale, private sector-managed funds-of-funds. These funds-of-funds, in turn, invest in a range of VC funds supporting innovative, high-growth UK firms. BBI participates in closed-ended limited partnerships, investing on terms at least as favourable as private investors. To align fund managers’ incentives with BBI’s goals, part of their compensation depends on carried interest, and BBI holds representation on Limited Partnership Advisory Committees (British Business Investments, 2018[11]). The programme has a total funding commitment of GBP 500 million, remaining open until all funds are allocated. As of April 2023, GBP 431 million had been committed to seven funds (British Business Investment, 2024[28]).
On the other hand, the British Patient Capital (BPC) Programme addresses the shortage of long-term financing through investments in VC funds (in contrast to the MFP, which invests in large-scale funds-of-funds). The BPC invests on a pari-passu basis and into fixed-term Limited Partnership funds but also supports evergreen funds. Its investments span two stages: venture funds for early-stage funding (pre-seed to Series A) and growth funds for later-stage financing (Series B+). In 2022, the programme shifted its focus, targeting two-thirds of its investments in growth-stage companies. Although BPC is sector-agnostic, its portfolio predominantly includes deep tech, life sciences, and financial services. Net zero, diversity, and regional equity are not explicit goals of the programme (British Business Bank, 2018[29]) (British Business Bank, 2022[30]). BPC received an initial capital investment of GBP 2.5 billion in 2018 and was expected to unlock an additional GBP of 5 billion from private investors (1:2 leverage ratio). As of 2022, BPC’s total investments had reached GBP 1.6 billion, while AUM were GBP 3.1 billion, mostly dispersed across 61 different private VC funds (Kimmo, 2023[31]).
A 2022 evaluation of the programme revealed that BPC-supported financing improved the efficiency of equity financing. Companies accessed funding more quickly and at larger scales, primarily using it for growth, R&D, and commercialization. BPC investments had significant positive impacts on recipient companies, including 55% employment growth on average, a net increase in turnover between GBP 4.7 million and GBP 5.4 million, and an average increase of GBP 60 million in valuations. However, deal sizes aligned with BPC’s objectives were at the lower end of the identified funding gap (GBP 5 million) and funds in the portfolio from 2013 to 2019 had not matched the performance of the broader UK VC market (British Business Bank, 2023[12]).
In November 2023, the UK government announced the creation of a new fund under the Long-term Investment in Technology and Science (LIFTS) initiative, managed by the BBB. This initiative aims to attract pension schemes and asset managers to invest in science and technology companies, as part of broader reforms to unlock savings for economic growth. As part of this initiative, the first Long-Term Asset Fund (LTAF) dedicated to providing venture capital to late-stage technology and science-focused companies was launched in September 2024 (British Business Bank, 2024[14]).